Cargando…
SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer
BACKGROUND: Metastatic breast cancer exhibits diverse and rapidly evolving intra- and inter-tumor heterogeneity. Patients with similar clinical presentations often display distinct tumor responses to standard of care (SOC) therapies. Genome landscape studies indicate that EGFR/HER2/RAS “pathway” act...
Autores principales: | van Reesema, Lauren L. Siewertsz, Zheleva, Vasilena, Winston, Janet S., Jansen, Rick J., O’Connor, Carolyn F., Isbell, Andrew J., Bian, Minglei, Qin, Rui, Bassett, Patricia T., Hinson, Virginia J., Dorsch, Kimberly A., Kirby, Brad W., Van Sciver, Robert E., Tang-Tan, Angela M., Harden, Elizabeth A., Chang, David Z., Allen, Cynthia A., Perry, Roger R., Hoefer, Richard A., Tang, Amy H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049993/ https://www.ncbi.nlm.nih.gov/pubmed/27569656 http://dx.doi.org/10.1016/j.ebiom.2016.08.014 |
Ejemplares similares
-
A New Strategy to Control and Eradicate “Undruggable” Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology
por: Van Sciver, Robert E., et al.
Publicado: (2018) -
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies
por: Gupta, Gagan K., et al.
Publicado: (2020) -
Phylogenetic analysis of the SINA/SIAH ubiquitin E3 ligase family in Metazoa
por: Pepper, Ian J., et al.
Publicado: (2017) -
Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer
por: Tang, Amy H., et al.
Publicado: (2022) -
Investigating the Molecular Basis of Siah1 and Siah2 E3 Ubiquitin Ligase Substrate Specificity
por: Gopalsamy, Anupriya, et al.
Publicado: (2014)